Top 5 Articles About Weight-Loss Drugs in 2023
Weight-loss medications were very much in the news this year, and the pages and website of Managed Healthcare Executive were no exception. Articles on off-label use of the GLP-1s such as Ozempic (semaglutide) and the FDA approval of Zepbound (tirzepatide) garnered the most page views.
For Weight Loss, Off-Label GLP-1s Are Increasingly the Chosen Ones | AMCP 2023
They are the trendy way to lose weight, and payers have been noticing an increase in GLP-1 claims. An analysis of the pharmacy and healthcare claims of a small commercial health plan in Texas documents the growth in the off-label usage of the GLP-1s, such as Ozempic, for weight loss.
Coping With the Ozempic-Wegovy-Mounjaro Tsunami
Insurers are using prior authorization and other managed care strategies to control costs associated with the growing number of prescriptions, on- and off-label, for the weight-loss medications.
Trial Investigates Weight Loss Drug for Patients with Heart Failure
Patients with heart failure and obesity who were administered semaglutide experienced better results — they reported fewer symptoms, felt less physically limited, lost more weight, and could walk longer in a 6-minute test.
FDA Approves Zepbound, New Weight Loss Drug
Tirzepatide, with the brand name Zepbound, is expected to be available by the end of the year in six doses at a list price of $1,059.87, which is about 20% lower than semaglutide.
How Prime Therapeutics Tugged on the Reins of the Galloping GLP-1 Spend | AMCP Nexus 2023
The Minnesota-based pharmacy benefit manager says a program that resulted in patients switching from two incretin therapy prescriptions to one yielded $7,500 in savings per patient and a total of $3.5 million.
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Conversations with Perry and Friends: Saar Mahna, J.D., MBA
July 31st 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the "Conversations with Perry and Friends" podcast. In this episode, Cohen speaks with Saar Mahna, J.D., MBA, CEO and founder of Banjo Health, an artificial intelligence company focused on prior authorization.
Listen
First-in-Class Therapy for Diabetic Retinopathy Shows Six-Month Benefit | ASRS 2025
July 31st 2025PER-001, delivered through a slow-release, dissolvable implant in the vitreous cavity of the eye, is designed to block endothelin signaling to increase ocular blood flow and prevent vision loss.
Read More
Conversations With Perry and Friends: Paul Fronstin, Ph.D.
July 31st 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. In this episode, his guest is Paul Fronstin, Ph.D., director of health benefits research at the Employee Benefit Research Institute.
Listen
